GeneDx vs SOPHiA GENETICS (2026)
Both apply models to genomic interpretation and they sell to different parts of the same institution. GeneDx is a diagnostic service for rare disease, applying AI and expert variant interpretation to exome and genome sequencing, and it is measured on diagnostic yield, how many previously undiagnosed patients get an answer. SOPHiA is analysis infrastructure, a cloud native platform applying machine learning to call, annotate and interpret variants over sequencing a laboratory runs itself. So the question is whether you are sending cases out or building capability in. The exposure they share and neither resolves is ancestral representation: reference databases skew heavily European, variants of uncertain significance come back more often for everyone else, and neither vendor publishes yield or interpretation performance by ancestry. That is the number to demand from both.
- The clinical purpose is rare disease diagnosis rather than platform infrastructure, with variant interpretation combining models and expert review on exome and genome sequencing.
- The diagnostic yield question is the one that matters for this buyer, and a rare disease programme is measured on how many undiagnosed patients get an answer rather than on how many samples it can process.
- For a paediatric or rare disease service, the interpretation depth is the product, and that is a different asset from the sequencing itself.
- The platform applies machine learning with patented algorithms to call, annotate and interpret variants across a hospital's own sequencing, so the institution keeps the workflow rather than sending it out.
- It is cloud native and sold as analysis infrastructure, which suits a laboratory building its own genomics capability rather than outsourcing cases.
- As a listed company it carries the financial disclosure obligations that a private counterpart does not, which is worth something when you are committing a laboratory workflow to a platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. GeneDx and SOPHiA GENETICS are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | GeneDx | SOPHiA GENETICS |
|---|---|---|
| Primary category | Diagnostics & Genomics | Diagnostics & Genomics |
| Founded | Not recorded | 2011 |
| Headquarters | Gaithersburg, Maryland | Boston, Massachusetts |
| Website | genedx.com | sophiagenetics.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards GeneDx its top capability grade on Clinical and Operational Evidence, HIPAA and BAA Posture and Setting and Specialty Coverage. Set against SOPHiA GENETICS, GeneDx grades higher on Clinical and Operational Evidence, HIPAA and BAA Posture and Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards SOPHiA GENETICS its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against GeneDx, SOPHiA GENETICS grades higher on AI Centrality, Security Certifications and Trust Center and Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose GeneDx or SOPHiA GENETICS?
On the axes where the AI Health Index separates them, GeneDx grades higher on Clinical and Operational Evidence, HIPAA and BAA Posture and Setting and Specialty Coverage, and SOPHiA GENETICS grades higher on AI Centrality, Security Certifications and Trust Center and Deployment Model and Data Residency. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do GeneDx and SOPHiA GENETICS differ most?
The widest separation the AI Health Index records between GeneDx and SOPHiA GENETICS is on Security Certifications and Trust Center, where GeneDx grades C and SOPHiA GENETICS grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do GeneDx and SOPHiA GENETICS grade the same?
The AI Health Index grades GeneDx and SOPHiA GENETICS the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
Both records depend on variant interpretation, where the central and largely unaddressed exposure is ancestral representation: reference databases and published variant evidence are drawn disproportionately from European ancestry populations, so variants of uncertain significance are returned more often for everyone else, and a diagnostic yield figure means little without the ancestry composition of the cohort behind it. Ask both vendors for yield by ancestry.
Genomic data is also permanent, cannot be revoked once disclosed, and carries implications for biological relatives who never consented, which makes the retention and secondary use terms more consequential here than in most of this index.